Keyphrases
Retrospective Analysis
100%
Metastatic Soft Tissue Sarcoma
100%
Checkpoint Inhibitors
100%
Partial Response
75%
Undifferentiated Pleomorphic Sarcoma
75%
Complete Response
50%
Stable Disease
50%
Soft Tissue Sarcoma
50%
Ipilimumab
50%
Nivolumab
50%
Leiomyosarcoma
50%
Response Rate
25%
Median Overall Survival
25%
Median Progression-free Survival
25%
Retrospective Review
25%
Patient Characteristics
25%
Safety Factor
25%
Logistic Regression Model
25%
Safety Efficacy
25%
Prognostic Factors
25%
Sarcoma
25%
Treating Physicians
25%
Prior Treatment
25%
Anti-PD-1 Therapy
25%
Treatment Factors
25%
Multiple Cancers
25%
Cox Regression Model
25%
Baseline Factors
25%
Combination Immunotherapy
25%
Fibroblastic
25%
Pembrolizumab
25%
Best Overall Response
25%
Alveolar Soft Part Sarcoma
25%
Characteristic Prior
25%
Pleomorphic Leiomyosarcoma
25%
Efficacy Factor
25%
Sclerosing Epithelioid Fibrosarcoma
25%
Myxofibrosarcoma
25%
Medicine and Dentistry
Immunotherapy
100%
Soft Tissue Sarcoma
100%
Leiomyosarcoma
60%
Connective Tissue Cancer
60%
Ipilimumab
40%
Nivolumab
40%
Fibrosarcoma
40%
Diseases
40%
Progression Free Survival
20%
Overall Survival
20%
Patient Characteristics
20%
Prognostic Factor
20%
Proteus Syndrome
20%
Pembrolizumab
20%
Alveolar Soft Part Sarcoma
20%
Cox Regression Model
20%